Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com
Multidisciplinary Workflow Benefits Patients With Newly Diagnosed Pancreatic Cancer
November 15th 2022Early experience with a newly designed pancreatic cancer multidisciplinary clinic workflow at Roswell Park Comprehensive Cancer Center in Buffalo, New York, showed significant improvement in terms of time to subspecialty evaluation.
Read More
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
November 14th 2022In treating patients with locally advanced non–small cell lung cancer, one must consider multiple factors when deciding whether to treat them with immunotherapy or a targeted approach, even though the optimal treatment sequence has yet to be definitively established.
Read More
PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer
November 10th 2022The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.
Read More
Frontline Setting Boasts Multiple Treatment Options for Patients With ALL
November 9th 2022Clinicians treating patients with newly diagnosed acute lymphocytic leukemia now have multiple options at their disposal, including tyrosine kinase inhibitors, blinatumomab, and multiagent chemotherapy-based regimens, with more options aiming to enter the treatment paradigm.
Read More
Investigators Lay Groundwork for Exploring TROP-2 as a Therapeutic Target in NSCLC
October 6th 2022Clinicians looking for additional options for the treatment of patients with non–small cell lung cancer may soon be gaining another actionable biomarker with the emergence of exciting new data concerning targeting the cell-surface glycoprotein TROP-2.
Read More
Patritumab Deruxtecan Looks to Make an Impact in NSCLC Treatment Paradigm with HERTHENA-Lung02
September 30th 2022Investigators have set their sights on confirming the viability of HER3 as a clinically actionable therapeutic target for the treatment of patients with EGFR-mutant advanced non–small cell lung cancer, with the initiation of the phase 3 HERTHENA-Lung02 trial evaluating patritumab deruxtecan.
Read More
PRMT5 Inhibitor Exhibits Efficacy and Tolerability in NHL, Advanced Solid Tumors
September 12th 2022GSK3326595, a PRMT5 inhibitor, displayed modest efficacy and safety signals that were consistent with those that were previously reported with the agent among patients with advanced solid tumors.
Read More
Naporafenib Combinations Prove Effective in NRAS-Mutant Unresectable/Metastatic Melanoma
September 10th 2022The investigational type II RAF inhibitor naporafenib exhibited favorable efficacy with a tolerable safety profile in combination with rineterkib, trametinib, or ribociclib in patients with previously treated, unresectable or metastatic melanoma.
Read More
CLDN6 CAR T-Cell Therapy Shows Encouraging Efficacy in Relapsed/Refractory Advanced Solid Tumors
September 9th 2022The investigational carcinoembryonic antigen claudin 6 (CLDN6)–directed CAR T-cell therapy BNT211-01 displayed clinical activity both as monotherapy and in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.
Read More
AI-Powered Focal Therapy Maps Future Treatment Paradigm in Prostate Cancer
September 8th 2022For clinicians tasked with treating patients with prostate cancer, disease visualization has traditionally consisted of imprecise techniques such as MRI. However, a new artificial intelligence-based approach by Avenda Health is poised to potentially revolutionize the treatment landscape in the field.
Read More
Multiple Myeloma Armamentarium Is Set to Explode as Novel Agents Show Encouraging Early Data
August 27th 2022Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.
Read More
Long-Term Treatment with Daratumumab Plus Lenalidomide/Dexamethasone Boosts OS Benefits in Myeloma
August 26th 2022Treatment with daratumumab plus lenalidomide and dexamethasone for at least 18 months led to deep clinical responses in patients with treatment-naïve multiple myeloma who were transplant ineligible.
Read More
Advances in Site Self-Assessment Tools Aim to Bolster Equity in Clinical Trials
August 4th 2022National Cancer Institute-designated comprehensive cancer centers routinely perform clinical trial site self-assessments. However, participation in these types of assessments is far less commonplace among community oncology sites.
Read More
HER3 Emerges as Intriguing Treatment Target in Lung Cancer
August 3rd 2022HER3 has been shown to have a small amount of tyrosine kinase activity, making it an attractive target for the treatment of patients who have progressed after treatment with tyrosine kinase inhibitors. Preclinical data have shown that targeting HER3 and EGFR can overcome acquired resistance to EGFR inhibition.
Read More
Value of Biomarkers for Immunotherapy in Advanced NSCLC Continue to Evolve
July 28th 2022Traditional predictive biomarkers for the efficacy of peri-operative immunotherapy for patients with advanced non–small cell lung cancer, such as PD-L1 expression, still hold value but newer biomarker candidates such as minimal residual disease are starting to make an impact.
Read More
CDK4/6 Inhibitors Could Fill Treatment Void for Patients with HR+/HER2- Early Breast Cancer
July 22nd 2022Joyce O'Shaughnessy, MD, outlines the current role and ongoing research of CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative early stage breast cancer.
Read More